Physician profile
Alberto Comas Espinal
NPI 1679502785
$1,409.18
in general payments reported to CMS, 2019-2025
15 companies · $78.58 in 2025
The $78.58 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $312 · 2021: $333 · 2022: $152 · 2023: $41.71 · 2024: $73.01 · 2025: $78.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $382.10 | 2019-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $289.54 | 2020-2021 | |
| Glaxosmithkline, LLC. | $251.39 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.21 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $59.65 | 2019-2025 | Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $57.84 | 2019-2023 | |
| Lilly USA, LLC | $46.74 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $39.24 | 2024-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $33.74 | 2020 | |
| Abbvie INC. | $26.95 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.00 | 2024 | |
| Genentech USA, INC. | $19.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.36 | 2022 | |
| Phadia US INC. | $14.28 | 2021 | |
| Pfizer INC. | $13.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Comas Espinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.